Armata Pharmaceuticals, Inc. (ARMP) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Armata Pharmaceuticals reported revenue of $0. Net income was -$173.8M, or -$4.80 per diluted share. Operating activities generated -$25.8M of cash, leaving -$26.3M of free cash flow. At fiscal year end, Armata Pharmaceuticals held $76.9M in total assets against $295.5M in total liabilities, including $8.7M of cash and equivalents.
Open the full interactive Armata Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Armata Pharmaceuticals Key Stats
| Share Price | $3.10 |
|---|---|
| Market Cap | $192.3M |
| 52-Week Range | $3.10 – $14.80 |
| Shares Outstanding | 36.7 million (basic, 2026 Q2) |
Armata Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$21.6M | -$23.8M | -$36.9M | -$40.9M | -$42.4M | -$36.6M |
| Pre-Tax Income | -$22.2M | -$23.2M | -$36.9M | -$69,045 | -$18.9M | -$173.8M |
| Income Tax | — | — | — | $69.0M | — | — |
| Net Income | -$22.2M | -$23.2M | -$36.9M | -$69.0M | -$18.9M | -$173.8M |
| Diluted EPS | -$1.35 | -$0.96 | -$1.08 | -$1.91 | -$0.89 | -$4.80 |
Armata Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$26.7M | -$124.3M | -$115.3M | $74.1M |
| Diluted EPS | -$0.74 | -$3.43 | -$3.16 | -$0.27 |
Armata Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.6M | $10.3M | $14.9M | $13.5M | $9.3M | $8.7M |
| Current Assets | $10.8M | $15.0M | $27.0M | $19.2M | $11.3M | $10.7M |
| Total Assets | $39.5M | $69.8M | $95.8M | $98.4M | $86.4M | $76.9M |
| Current Liabilities | $6.7M | $4.8M | $24.9M | $16.5M | $48.2M | $8.9M |
| Total Long-Term Debt | — | — | — | $82.3M | $55.4M | $256.9M |
| Total Liabilities | $20.7M | $44.4M | $59.8M | $130.4M | $134.5M | $295.5M |
| Shareholders' Equity | $18.9M | $25.4M | $36.1M | -$32.1M | -$48.0M | -$218.6M |
Armata Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$18.3M | -$23.6M | -$32.5M | -$47.4M | -$37.6M | -$25.8M |
| Cash From Investing | -$824,000 | -$1.3M | -$2.2M | -$8.1M | -$1.9M | -$542,000 |
| Cash From Financing | $23.2M | $25.5M | $44.0M | $54.0M | $35.0M | $25.6M |
| Free Cash Flow | -$19.1M | -$24.9M | -$34.7M | -$55.6M | -$39.4M | -$26.3M |
Figures from Armata Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Armata Pharmaceuticals financials page for every line item.
Armata Pharmaceuticals Company Profile
| Ticker | ARMP |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Los Angeles, California |
| Incorporated in | Washington |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000921114 |
Frequently Asked Questions
What was Armata Pharmaceuticals' revenue in fiscal 2025?
Armata Pharmaceuticals (ARMP) reported revenue of $0 for fiscal 2025.
What is Armata Pharmaceuticals' annual revenue history?
Armata Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Armata Pharmaceuticals' net income in fiscal 2025?
Armata Pharmaceuticals reported net income of -$173.8M for fiscal 2025.
What was Armata Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Armata Pharmaceuticals' diluted EPS was -$4.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Armata Pharmaceuticals generate in fiscal 2025?
Armata Pharmaceuticals generated -$26.3M of free cash flow in fiscal 2025.
What was Armata Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Armata Pharmaceuticals reported revenue of $0.
How much debt does Armata Pharmaceuticals have?
Armata Pharmaceuticals reported $256.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Armata Pharmaceuticals are outstanding?
Armata Pharmaceuticals reported a weighted average of 36.7 million basic shares outstanding in 2026 Q2.
What is Armata Pharmaceuticals' market cap?
Based on its latest closing price, Armata Pharmaceuticals (ARMP) has a market capitalization of about $192.3M.
When does Armata Pharmaceuticals' fiscal year end?
Armata Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Armata Pharmaceuticals headquartered?
Armata Pharmaceuticals lists its business address in Los Angeles, California in its SEC filings.
Armata Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →